HKU Scholars Hub: Browsing DSpace

Browsing by Author Gaggar, A

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 12 of 12

	Title	Author(s)	Issue Date	Views
	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV Journal:PLoS One	Pan, CQ Chang, TT Bae, SH Brunetto, M Seto, WK Coffin, CS Tan, SK Mo, S Flaherty, JF Gaggar, A Nguyen, MH Celen, MK Thompson, A Gane, EJ Bulterys, M	2021	12
	Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) Proceeding/Conference:Hepatology	Seto, WKW Buti, M Izumi, N Lim, YS Kao, JH Streinu-Cercel, A Nurmukhametova, E Ma, X Tabak, F Jablkowski, M Suri, V Flaherty, JF Lau, AH Gaggar, A Mo, S Chowdhury, A Fung, SK Chuang, WL Gane, EJ	2018	73
	Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) Proceeding/Conference:Gut	Chan, HLY Seto, WKW Buti, M Izumi, N Lim, YS Kao, J Streinu-Cercel, A Nurmukhametova, E Ma, X Tabak, F Jablkowski, M Suri, V Flaherty, J Lau, A Gaggar, A Mo, S Chowdhury, A Fung, S Chuang, W Gane, E	2019	63
	IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) Proceeding/Conference:Hepatology	Lim, Y Chan, HLY Seto, WKW Ning, Q Agarwal, K Janssen, HL Pan, CQ Chuang, WL Izumi, N Fung, SK Shalimar,Brunetto, MR Flaherty, JF Mo, S Cheng, C Lin, L Gaggar, A Subramanian, M Marcellin, P Gane, EJ Hou, J Buti, M	2019	119
	Reduced changes in bone mineral density in Chronic HBV (CHB) Patients receiving Tenofovir Alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF) Proceeding/Conference:The Liver Meeting® 2016	Seto, WKW Asahina, Y Peng, CY Stanciu, C Abdurakhmanov, D Flaherty, J Kim, K Gaggar, A Subramanian, M Tabak, F Nguyen, TT Chan, HLY	2016	81
	Reduced changes in bone mineral density in chronic hepatitis B patients receiving TAF compared with TDF Proceeding/Conference:Conference of the Asian Pacific Association for the Study of the Liver, APASL 2017	Seto, WKW Asahina, Y Peng, CY Stanciu, C Abdurakhmanov, D Flaherty, J Kim, L Gaggar, A Subramanian, M Tabak, F Nguyen, TT Chan, HLY	2017	45
	RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection Journal:Clinical Gastroenterology and Hepatology	Seto, WKW Asahina, Y Brown, TT Peng, CY Stanciu, C Abdurakhmanov, D Tabak, F Nguyen, TT Chuang, WL Inokuma, T Ikeda, F Santantonio, TA Habersetzer, F Ramji, A Lau, AH Suri, V Flaherty, JF Wang, H Gaggar, A Subramanian, GM Mukewar, S Brunetto, MR Fung, S Chan, HL	2018	50
	Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use Proceeding/Conference:Journal of Hepatology	Gane, E Seto, WKW Janssen, H Carantu, FA Kim, HJ Abdurakhmanov, D Nishiguchi, S Andrzej, H Bae, H Mo, S Suri, V Gaggar, A Flaherty, JF Kao, JH Brunetto, M Ferret, MB	2018	88
	Tenofovir alafenamide (TAF) compared with Tenofovir Dispoproxil Fumarate (TDF) in patients with chronic HBV: week 96 efficacy and safety results in Chinese patients enrolled in 2 overseas phase 3 studies Proceeding/Conference:Chinese Infectious Disease and Hepatology Conference	Seto, WKW Fung, S Hou, J Pan, C Chuang, WL Chang, TT Hui, AJ Chen, CY Ma, X Tam, E Tsang, TY Yang, J Flaherty, JF Gaggar, A Mo, S Tong, M Kao, JH Chan, HL	2017
	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology	Chan, HL Fung, S Seto, WKW Chuang, WL Chen, CY Kim, HJ Hui, AJ Janssen, H Chowdhury, A Tsang, TY Rajiv, M Gane, E Flaherty, J Massetto, B Gaggar, A Kitrinos, KM Lin, L Subramanian, GM McHutchison, J Lim, YS Acharya, SK Agarwal, K	2016	76
	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology	Buti, M Gane, E Seto, WKW Chan, HL Chuang, WL Stepanova, T Hui, AJ Lim, YS Mehta, R Janssen, H Acharya, SK Flaherty, J Massetto, B Cathcart, AL Kim, K Gaggar, A Subramanian, GM McHutchison, J Pan, C Brunetto, M Izumi, N Marcellin, P	2016
	Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B Proceeding/Conference:Hepatology	Chan, HLY Lim, YS Seto, WKW Agarwal, K Brunetto, MR Janssen, HLA Caruntu, F Stepanova, T Tsang, O Yatsuhashi, H Tak, WY Chen, CY Celen, M Sun, V Flaherty, JF Lin, L Cathcart, A Gaggar, A Pan, CQ Shalimar Buti, M	2018

Showing results 1 to 12 of 12